Regenicin, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020
August 19, 2020 at 04:26 pm
Share
Regenicin, Inc. announced earnings results for the third quarter ended June 30, 2020. For the third quarter, the company announced operating loss was USD 162,054 compared to USD 176,234 a year ago. Net loss was USD 171,838 compared to USD 182,871 a year ago. For the nine months, operating loss was USD 517,262 compared to USD 591,387 a year ago. Net loss was USD 558,472 compared to USD 608,528 a year ago.
Regenicin, Inc. is a biotechnology company that is focused on the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. It is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas in patients, such as ulcers. Its application is used for the treatment of chronic skin wounds.